Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey
Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …
2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing …
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19
1 Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC–high bleeding risk trade-off model
P Urban, J Gregson, R Owen, R Mehran… - JAMA …, 2021 - jamanetwork.com
Importance Patients who are candidates for percutaneous coronary intervention (PCI) and
are at high bleeding risk constitute a therapeutic challenge because they often also face an …
are at high bleeding risk constitute a therapeutic challenge because they often also face an …
[HTML][HTML] Brazilian Society of cardiology guidelines on unstable angina and acute myocardial infarction without ST-segment elevation–2021
JC Nicolau, GS Feitosa Filho, JL Petriz… - Arquivos brasileiros de …, 2021 - SciELO Brasil
SciELO - Brasil - Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e
Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021 Diretrizes da …
Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021 Diretrizes da …
Effect of adjusted antiplatelet therapy on preventing ischemic events after stenting for intracranial aneurysms
W Li, W Zhu, A Wang, G Zhang, Y Zhang, K Wang… - Stroke, 2021 - Am Heart Assoc
Background and Purpose: This study tests whether patients with unruptured intracranial
aneurysm who underwent stent placement benefitted from platelet function monitoring …
aneurysm who underwent stent placement benefitted from platelet function monitoring …
Ticagrelor versus clopidogrel in the dual antiplatelet regimen for intracranial stenting or flow-diverter treatment for unruptured cerebral aneurysms: a single-center …
KY Park, T Ozaki, A Kostynskyy… - American Journal …, 2021 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known
about its efficacy and safety in the endovascular treatment of aneurysms. This study …
about its efficacy and safety in the endovascular treatment of aneurysms. This study …
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations
Introduction Clopidogrel is the most frequently utilized P2Y12 inhibitor and is characterized
by broad interindividual response variability resulting in impaired platelet inhibition and …
by broad interindividual response variability resulting in impaired platelet inhibition and …
[HTML][HTML] MicroRNA as potential biomarkers of platelet function on antiplatelet therapy: a review
P Czajka, A Fitas, D Jakubik, C Eyileten… - Frontiers in …, 2021 - frontiersin.org
MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by
specific gene modifications. Platelets are the major source for circulating miRNAs, with …
specific gene modifications. Platelets are the major source for circulating miRNAs, with …